Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 versus AMINOSYN II 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 versus AMINOSYN II 7.
AMINOSYN II 10% vs AMINOSYN II 7%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and nitrogen balance maintenance in patients unable to tolerate adequate oral/enteral intake.
Aminosyn II 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for protein synthesis and supports metabolic functions in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion: 500 mL to 1 L of 10% solution (50-100 g amino acids) per day, administered at a rate not exceeding 100 mL/h. Typical initial dose: 0.8-1.5 g/kg/day of amino acids, adjusted based on metabolic needs and tolerance.
Intravenous infusion; typical adult dose: 0.8-1.5 g amino acids/kg/day (11.4-21.4 mL/kg/day of 7% solution); rate not exceeding 0.1 g amino acids/kg/hour.
None Documented
None Documented
Variable depending on metabolic state; for individual amino acids, half-lives range from 10 to 100 minutes. In renal impairment, accumulation can occur. No single terminal half-life for the mixture.
Not applicable; exogenous amino acids are rapidly cleared from plasma with a terminal half-life of 15-20 minutes for individual amino acids.
Primarily renal as amino acids and metabolites; >90% of infused amino acids are reabsorbed by proximal tubules, with less than 10% excreted unchanged in urine. Biliary/fecal excretion negligible.
Renal as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution